An observational study in Hypertension, sponsored by Boehringer Ingelheim. Completed. Per ClinicalTrials.gov, last updated 2014-09-19.
Sponsored by Boehringer Ingelheim · Observational
The objective of this PMS study was to monitor and assess the safety of Micardis tablets in patients with hypertension over a period of 6 years
6,689 studies on the registry are indexed under Hypertension; 965 are open to participants now.
This study's enrollment of 13,066 is above the median of 210 across 1,359 observational studies indexed under Hypertension.
Browse Hypertension studies →Boehringer Ingelheim is the lead sponsor of 2,245 studies on the registry; 58 are open to participants now.
Of its 162 completed or terminated interventional studies of FDA-regulated products, 116 (72%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients with essential hypertension and without prior Micardis experience
Exclusion Criteria:
Drug: Telmisartan
Blood pressure reduction
Time frame: Up to 6 years
Final assessment of efficacy on a 3-point scale
Time frame: Up to 6 years
Assessment of efficacy based on subject's demographics on a two-point scale
Time frame: Up to 6 years
Number of patients with adverse events
Time frame: Up to 6 years
Incidence rate of adverse events
based on demographic factors
Time frame: Up to 6 years
Assessment of safety on a 4-point scale
based on adverse events and changes in abnormality of clinical laboratory tests
Time frame: Up to 6 years
No study locations are listed for this record.
This study is completed, as verified in Sep 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Boehringer Ingelheim